Clinical trial · no report yet · Phase 3
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- NCT04704934 ↗
- Active not recruiting
- Daiichi Sankyo
- 137 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 59 | |
| X threads | 43 | |
| Podcasts | 34 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
- Interventions
- Trastuzumab deruxtecan; Ramucirumab; Paclitaxel
- Arms
- Trastuzumab deruxtecan · Experimental
- Ramucirumab + paclitaxel · Active comparator
- Enrollment
- 490 (estimated)
- Primary outcomes
- Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel
- Sponsor
- Daiichi Sankyo with AstraZeneca
- Start
- May 21, 2021
- Primary completion
- Aug 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04704934 · updated May 27, 2026
Publications
linked from the registry- Shitara K, Van Cutsem E, Gumus M, Lonardi S, de la Fouchardiere C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31. PubMed 40454632
- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124